The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair–Deficient Cancer: Results From the Phase II KEYNOTE-158 Study
Open accessAbstract
PURPOSE: Genomes of tumors that are deficient in DNA mismatch repair (dMMR) have high microsatellite instability (MSI-H) and harbor hundreds to thousands of somatic mutations that encode potential neoantigens. Such tumors are therefore likely to be immunogenic, triggering upregulation of immune checkpoint proteins. Pembrolizumab, an anti‒programmed death-1 monoclonal antibody, has antitumor activity against MSI-H/dMMR cancer. We report data from the phase II KEYNOTE-158 study of pembrolizumab in patients with previously treated, advanced noncolorectal MSI-H/dMMR cancer. PATIENTS AND METHODS: Eligible patients with histologically/cytologically confirmed MSI-H/dMMR advanced noncolorectal cancer who experienced failure with prior therapy received pembrolizumab 200 mg once every 3 weeks for 2 years or until disease progression, unacceptable toxicity, or patient withdrawal. Radiologic imaging was performed every 9 weeks for the first year of therapy and every 12 weeks thereafter. The primary end point was objective response rate per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, as assessed by independent central radiologic review. RESULTS: Among 233 enrolled patients, 27 tumor types were represented, with endometrial, gastric, cholangiocarcinoma, and pancreatic cancers being the most common. Median follow up was 13.4 months. Objective response rate was 34.3% (95% CI, 28.3% to 40.8%). Median progression-free survival was 4.1 months (95% CI, 2.4 to 4.9 months) and median overall survival was 23.5 months (95% CI, 13.5 months to not reached). Treatment-related adverse events occurred in 151 patients (64.8%). Thirty-four patients (14.6%) had grade 3 to 5 treatment-related adverse events. Grade 5 pneumonia occurred in one patient; there were no other treatment-related fatal adverse events. CONCLUSION: Our study demonstrates the clinical benefit of anti–programmed death-1 therapy with pembrolizumab among patients with previously treated unresectable or metastatic MSI-H/dMMR noncolorectal cancer. Toxicity was consistent with previous experience of pembrolizumab monotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Self-citationComprehensive molecular characterization of human colon and rectal cancer
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11252 · Cited by 8,499
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645 · cited 3×
“The pattern of immunemediated adverse events and infusion reactions was as anticipated after pembrolizumab administration and was consistent with that observed previously across multiple tumor types.(7,17) Grade 3 or 4 immune-mediated adverse events occurred in 14 patients and were overall manageable as most were grad…”
BackgroundResultSelf-citationOverman, M. J., McDermott, R., Leach, J. L., Lonardi, S., Lenz, H.-J., Morse, M. A., Desai, J., Hill, A., Axelson, M., Moss, R. A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30422-9 · Cited by 2,836
Taube, J. M., Klein, A., Brahmer, J. R., Xu, H., Pan, X., Kim, J. H., Chen, L., Pardoll, D. M., Topalian, S. L., & Anders, R. A. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3271 · Cited by 2,324
Llosa, N. J., Cruise, M., Tam, A., Wicks, E. C., Hechenbleikner, E. M., Taube, J. M., Blosser, R. L., Fan, H., Wang, H., Luber, B. S., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0863 · Cited by 1,487
Landscape of Microsatellite Instability Across 39 Cancer Types
Bonneville, R., Krook, M. A., Kautto, E. A., Miya, J., Wing, M. R., Chen, H.-Z., Reeser, J. W., Yu, L., & Roychowdhury, S. (2017) · JCO Precision Oncology · doi:10.1200/po.17.00073 · Cited by 1,476
Microsatellite Instability as a Biomarker for PD-1 Blockade
Dudley, J. C., Lin, M.-T., Le, D. T., & Eshleman, J. R. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1678 · Cited by 931
Self-citationHowitt, B. E., Shukla, S. A., Sholl, L. M., Ritterhouse, L. L., Watkins, J. C., Rodig, S., Stover, E., Strickland, K. C., D’Andrea, A. D., Wu, C. J., et al. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.2151 · Cited by 684
First FDA Approval Agnostic of Cancer Site — When a Biomarker Defines the Indication
Lemery, S., Keegan, P., & Pazdur, R. (2017) · New England Journal of Medicine · doi:10.1056/nejmp1709968 · Cited by 664
Cited by
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer
André, T., Shiu, K.-K., Kim, T. W., Jensen, B. V., Jensen, L. H., Punt, C., Smith, D., Garcia-Carbonero, R., Benavides, M., Gibbs, P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2017699 · Cited by 3,099
Self-citationMarabelle, A., Fakih, M., Lopez, J., Shah, M., Shapira-Frommer, R., Nakagawa, K., Chung, H. C., Kindler, H. L., Lopez-Martin, J. A., Miller, W. H., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30445-9 · Cited by 2,552
Self-citationESGO/ESTRO/ESP Guidelines for the Management of Patients with Endometrial Carcinoma
Concin, N., Matias-Guiu, X., Vergote, I., Cibula, D., Mirza, M. R., Marnitz, S., Ledermann, J., Bosse, T., Chargari, C., Fagotti, A., et al. (2021) · International Journal of Gynecological Cancer · doi:10.1136/ijgc-2020-002230 · Cited by 1,989
Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology
Ajani, J. A., D’Amico, T. A., Bentrem, D. J., Chao, J., Cooke, D., Corvera, C., Das, P., Enzinger, P. C., Enzler, T., Fanta, P., et al. (2022) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2022.0008 · Cited by 1,684
Current treatment and recent progress in gastric cancer
Joshi, S. S., & Badgwell, B. D. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21657 · Cited by 1,677
PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer
Cercek, A., Lumish, M., Sinopoli, J., Weiss, J., Shia, J., Lamendola-Essel, M., El Dika, I. H., Segal, N., Shcherba, M., Sugarman, R., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2201445 · Cited by 1,625
Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
Lordick, F., Carneiro, F., Cascinu, S., Fleitas, T., Haustermans, K., Piessen, G., Vogel, A., & Smyth, E. C. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.07.004 · Cited by 1,503
Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
Tempero, M. A., Malafa, M. P., Al-Hawary, M., Behrman, S. W., Benson, A. B., Cardin, D. B., Chiorean, E. G., Chung, V., Czito, B., Del Chiaro, M., et al. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.0017 · Cited by 1,304
Mosele, F., Remon, J., Mateo, J., Westphalen, C. B., Barlesi, F., Lolkema, M. P., Normanno, N., Scarpa, A., Robson, M., Meric-Bernstam, F., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.07.014 · Cited by 1,186
Kelley, R. K., Ueno, M., Yoo, C., Finn, R. S., Furuse, J., Ren, Z., Yau, T., Klümpen, H.-J., Chan, S. L., Ozaka, M., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)00727-4 · Cited by 1,169
Self-citationGanesh, K., & Massagué, J. (2021) · Nature Medicine · doi:10.1038/s41591-020-01195-4 · Cited by 1,051
McGrail, D. J., Pilié, P. G., Rashid, N. U., Voorwerk, L., Slagter, M., Kok, M., Jonasch, E., Khasraw, M., Heimberger, A. B., Lim, B., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.02.006 · Cited by 1,032
Le, D. T., Kim, T. W., Van Cutsem, E., Geva, R., Jäger, D., Hara, H., Burge, M., O’Neil, B., Kavan, P., Yoshino, T., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02107 · Cited by 1,005
Self-citationHepatobiliary Cancers, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
Benson, A. B., D’Angelica, M. I., Abbott, D. E., Anaya, D. A., Anders, R., Are, C., Bachini, M., Borad, M., Brown, D., Burgoyne, A., et al. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.0022 · Cited by 1,003
Acquired Resistance to Immune Checkpoint Inhibitors
Schoenfeld, A. J., & Hellmann, M. D. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.03.017 · Cited by 955
Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer
Makker, V., Colombo, N., Casado Herráez, A., Santin, A. D., Colomba, E., Miller, D. S., Fujiwara, K., Pignata, S., Baron-Hay, S., Ray-Coquard, I., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2108330 · Cited by 930
León-Castillo, A., de Boer, S. M., Powell, M. E., Mileshkin, L. R., Mackay, H. J., Leary, A., Nijman, H. W., Singh, N., Pollock, P. M., Bessette, P., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.00549 · Cited by 855
Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer
Eskander, R. N., Sill, M. W., Beffa, L., Moore, R. G., Hope, J. M., Musa, F. B., Mannel, R., Shahin, M. S., Cantuaria, G. H., Girda, E., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2302312 · Cited by 758
Review of precision cancer medicine: Evolution of the treatment paradigm
Tsimberidou, A. M., Fountzilas, E., Nikanjam, M., & Kurzrock, R. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102019 · Cited by 756
Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
Vogel, A., Bridgewater, J., Edeline, J., Kelley, R. K., Klümpen, H. J., Malka, D., Primrose, J. N., Rimassa, L., Stenzinger, A., Valle, J. W., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2022.10.506 · Cited by 718
Mechanisms and therapeutic implications of hypermutation in gliomas
Touat, M., Li, Y. Y., Boynton, A. N., Spurr, L. F., Iorgulescu, J. B., Bohrson, C. L., Cortes-Ciriano, I., Birzu, C., Geduldig, J. E., Pelton, K., et al. (2020) · Nature · doi:10.1038/s41586-020-2209-9 · Cited by 677
Self-citationTreatment of Metastatic Colorectal Cancer: ASCO Guideline
Morris, V. K., Kennedy, E. B., Baxter, N. N., Benson, A. B., Cercek, A., Cho, M., Ciombor, K. K., Cremolini, C., Davis, A., Deming, D. A., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.01690 · Cited by 682
Makker, V., MacKay, H., Ray-Coquard, I., Levine, D. A., Westin, S. N., Aoki, D., & Oaknin, A. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00324-8 · Cited by 674
Lu, K. H., & Broaddus, R. R. (2020) · New England Journal of Medicine · doi:10.1056/nejmra1514010 · Cited by 663
Neuroendocrine and Adrenal Tumors, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
Shah, M. H., Goldner, W. S., Benson, A. B., Bergsland, E., Blaszkowsky, L. S., Brock, P., Chan, J., Das, S., Dickson, P. V., Fanta, P., et al. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.0032 · Cited by 619
Self-citationThe Tumor Microenvironment in the Response to Immune Checkpoint Blockade Therapies
Petitprez, F., Meylan, M., de Reyniès, A., Sautès-Fridman, C., & Fridman, W. H. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00784 · Cited by 602
Prostate Cancer, Version 4.2023, NCCN Clinical Practice Guidelines in Oncology
Schaeffer, E. M., Srinivas, S., Adra, N., An, Y., Barocas, D., Bitting, R., Bryce, A., Chapin, B., Cheng, H. H., D’Amico, A. V., et al. (2023) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2023.0050 · Cited by 596
Ajani, J. A., D’Amico, T. A., Bentrem, D. J., Cooke, D., Corvera, C., Das, P., Enzinger, P. C., Enzler, T., Farjah, F., Gerdes, H., et al. (2023) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2023.0019 · Cited by 569
Bockorny, B., Semenisty, V., Macarulla, T., Borazanci, E., Wolpin, B. M., Stemmer, S. M., Golan, T., Geva, R., Borad, M. J., Pedersen, K. S., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0880-x · Cited by 557
Self-citationNCCN Guidelines Insights: Prostate Cancer, Version 1.2021: Featured Updates to the NCCN Guidelines
Schaeffer, E., Srinivas, S., Antonarakis, E. S., Armstrong, A. J., Bekelman, J. E., Cheng, H., D’Amico, A. V., Davis, B. J., Desai, N., Dorff, T., et al. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.0008 · Cited by 525
Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer
Makker, V., Taylor, M. H., Aghajanian, C., Oaknin, A., Mier, J., Cohn, A. L., Romeo, M., Bratos, R., Brose, M. S., DiSimone, C., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02627 · Cited by 522
O'Malley, D. M., Bariani, G. M., Cassier, P. A., Marabelle, A., Hansen, A. R., De Jesus Acosta, A., Miller, W. H., Safra, T., Italiano, A., Mileshkin, L., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.01874 · Cited by 516
Self-citationTumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons
Naimi, A., Mohammed, R. N., Raji, A., Chupradit, S., Yumashev, A. V., Suksatan, W., Shalaby, M. N., Thangavelu, L., Kamrava, S., Shomali, N., et al. (2022) · Cell Communication and Signaling · doi:10.1186/s12964-022-00854-y · Cited by 507
Stoop, T. F., Javed, A. A., Oba, A., Koerkamp, B. G., Seufferlein, T., Wilmink, J. W., & Besselink, M. G. (2025) · The Lancet · doi:10.1016/s0140-6736(25)00261-2 · Cited by 479
Maio, M., Ascierto, P. A., Manzyuk, L., Motola-Kuba, D., Penel, N., Cassier, P. A., Bariani, G. M., De Jesus Acosta, A., Doi, T., Longo, F., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.05.519 · Cited by 472
Self-citationTumor Microenvironment in Pancreatic Cancer Pathogenesis and Therapeutic Resistance
Sherman, M. H., & Beatty, G. L. (2023) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-031621-024600 · Cited by 467
Beyond immune checkpoint blockade: emerging immunological strategies
Kubli, S. P., Berger, T., Araujo, D. V., Siu, L. L., & Mak, T. W. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00155-y · Cited by 461
Immunotherapy for pancreatic cancer: A 2020 update
Schizas, D., Charalampakis, N., Kole, C., Economopoulou, P., Koustas, E., Gkotsis, E., Ziogas, D., Psyrri, A., & Karamouzis, M. V. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102016 · Cited by 458
Chao, J., Fuchs, C. S., Shitara, K., Tabernero, J., Muro, K., Van Cutsem, E., Bang, Y.-J., De Vita, F., Landers, G., Yen, C.-J., et al. (2021) · JAMA Oncology · doi:10.1001/jamaoncol.2021.0275 · Cited by 443
Self-citationEsophageal cancer practice guidelines 2022 edited by the Japan esophageal society: part 1
Kitagawa, Y., Ishihara, R., Ishikawa, H., Ito, Y., Oyama, T., Oyama, T., Kato, K., Kato, H., Kawakubo, H., Kawachi, H., et al. (2023) · Esophagus · doi:10.1007/s10388-023-00993-2 · Cited by 427
Primary brain tumours in adults
van den Bent, M. J., Geurts, M., French, P. J., Smits, M., Capper, D., Bromberg, J. E. C., & Chang, S. M. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01054-1 · Cited by 419
Paradigms on Immunotherapy Combinations with Chemotherapy
Salas-Benito, D., Pérez-Gracia, J. L., Ponz-Sarvisé, M., Rodriguez-Ruiz, M. E., Martínez-Forero, I., Castañón, E., López-Picazo, J. M., Sanmamed, M. F., & Melero, I. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1312 · Cited by 407
Pancreatic Cancer: A Review of Current Treatment and Novel Therapies
Kolbeinsson, H. M., Chandana, S., Wright, G. P., & Chung, M. (2023) · Journal of Investigative Surgery · doi:10.1080/08941939.2022.2129884 · Cited by 386
Antibody–drug conjugates: Smart chemotherapy delivery across tumor histologies
Tarantino, P., Carmagnani Pestana, R., Corti, C., Modi, S., Bardia, A., Tolaney, S. M., Cortes, J., Soria, J., & Curigliano, G. (2022) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21705 · Cited by 385
NCCN Guidelines® Insights: Cervical Cancer, Version 1.2024: Featured Updates to the NCCN Guidelines
Abu-Rustum, N. R., Yashar, C. M., Arend, R., Barber, E., Bradley, K., Brooks, R., Campos, S. M., Chino, J., Chon, H. S., Crispens, M. A., et al. (2023) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2023.0062 · Cited by 384
Westin, S. N., Moore, K., Chon, H. S., Lee, J.-Y., Thomes Pepin, J., Sundborg, M., Shai, A., de la Garza, J., Nishio, S., Gold, M. A., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.23.02132 · Cited by 380
Self-citationNeoadjuvant therapy for pancreatic cancer
Springfeld, C., Ferrone, C. R., Katz, M. H. G., Philip, P. A., Hong, T. S., Hackert, T., Büchler, M. W., & Neoptolemos, J. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00746-1 · Cited by 377
Milbury, C. A., Creeden, J., Yip, W.-K., Smith, D. L., Pattani, V., Maxwell, K., Sawchyn, B., Gjoerup, O., Meng, W., Skoletsky, J., et al. (2022) · PLOS ONE · doi:10.1371/journal.pone.0264138 · Cited by 376
Ovarian Cancer Immunotherapy and Personalized Medicine
Morand, S., Devanaboyina, M., Staats, H., Stanbery, L., & Nemunaitis, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126532 · Cited by 372
Wang, S., Zheng, Y., Yang, F., Zhu, L., Zhu, X.-Q., Wang, Z.-F., Wu, X.-L., Zhou, C.-H., Yan, J.-Y., Hu, B.-Y., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00659-4 · Cited by 369
Molecular targeted therapies: Ready for “prime time” in biliary tract cancer
Lamarca, A., Barriuso, J., McNamara, M. G., & Valle, J. W. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.03.007 · Cited by 367
Oaknin, A., Tinker, A. V., Gilbert, L., Samouëlian, V., Mathews, C., Brown, J., Barretina-Ginesta, M.-P., Moreno, V., Gravina, A., Abdeddaim, C., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2020.4515 · Cited by 364
Current developments in gastric cancer: from molecular profiling to treatment strategy
Alsina, M., Arrazubi, V., Diez, M., & Tabernero, J. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-022-00703-w · Cited by 350
Oaknin, A., Gilbert, L., Tinker, A. V., Brown, J., Mathews, C., Press, J., Sabatier, R., O’Malley, D. M., Samouelian, V., Boni, V., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003777 · Cited by 338
Development of Immunotherapy Combination Strategies in Cancer
Yap, T. A., Parkes, E. E., Peng, W., Moyers, J. T., Curran, M. A., & Tawbi, H. A. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1209 · Cited by 330
Immunotherapy combination approaches: mechanisms, biomarkers and clinical observations
Butterfield, L. H., & Najjar, Y. G. (2024) · Nature Reviews Immunology · doi:10.1038/s41577-023-00973-8 · Cited by 330
Neoadjuvant immune checkpoint blockade: A window of opportunity to advance cancer immunotherapy
Topalian, S. L., Forde, P. M., Emens, L. A., Yarchoan, M., Smith, K. N., & Pardoll, D. M. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.07.011 · Cited by 317
Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma
Qian, Y., Gong, Y., Fan, Z., Luo, G., Huang, Q., Deng, S., Cheng, H., Jin, K., Ni, Q., Yu, X., et al. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00958-3 · Cited by 312
Clinical trial design in the era of precision medicine
Fountzilas, E., Tsimberidou, A. M., Vo, H. H., & Kurzrock, R. (2022) · Genome Medicine · doi:10.1186/s13073-022-01102-1 · Cited by 305
Hu, H., Kang, L., Zhang, J., Wu, Z., Wang, H., Huang, M., Lan, P., Wu, X., Wang, C., Cao, W., et al. (2022) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(21)00348-4 · Cited by 302
Defining clinically useful biomarkers of immune checkpoint inhibitors in solid tumours
Holder, A. M., Dedeilia, A., Sierra-Davidson, K., Cohen, S., Liu, D., Parikh, A., & Boland, G. M. (2024) · Nature Reviews Cancer · doi:10.1038/s41568-024-00705-7 · Cited by 298
Parikh, A. R., Szabolcs, A., Allen, J. N., Clark, J. W., Wo, J. Y., Raabe, M., Thel, H., Hoyos, D., Mehta, A., Arshad, S., et al. (2021) · Nature Cancer · doi:10.1038/s43018-021-00269-7 · Cited by 294
Korean Practice Guidelines for Gastric Cancer 2022: An Evidence-based, Multidisciplinary Approach
Kim, T.-H., Kim, I.-H., Kang, S. J., Choi, M., Kim, B.-H., Eom, B. W., Kim, B. J., Min, B.-H., Choi, C. I., Shin, C. M., et al. (2023) · Journal of Gastric Cancer · doi:10.5230/jgc.2023.23.e11 · Cited by 288
DNA Sensing in Mismatch Repair-Deficient Tumor Cells Is Essential for Anti-tumor Immunity
Lu, C., Guan, J., Lu, S., Jin, Q., Rousseau, B., Lu, T., Stephens, D., Zhang, H., Zhu, J., Yang, M., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2020.11.006 · Cited by 285
Self-citationSubstitution mutational signatures in whole-genome–sequenced cancers in the UK population
Degasperi, A., Zou, X., Dias Amarante, T., Martinez-Martinez, A., Koh, G. C. C., Dias, J. M. L., Heskin, L., Chmelova, L., Rinaldi, G., Wang, V. Y. W., et al. (2022) · Science · doi:10.1126/science.abl9283 · Cited by 280
Chakravarty, D., Johnson, A., Sklar, J., Lindeman, N. I., Moore, K., Ganesan, S., Lovly, C. M., Perlmutter, J., Gray, S. W., Hwang, J., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02767 · Cited by 266
Luchini, C., Brosens, L. A. A., Wood, L. D., Chatterjee, D., Shin, J. I., Sciammarella, C., Fiadone, G., Malleo, G., Salvia, R., Kryklyva, V., et al. (2021) · Gut · doi:10.1136/gutjnl-2020-320726 · Cited by 258
Molecular Characterization of KRAS Wild-type Tumors in Patients with Pancreatic Adenocarcinoma
Philip, P. A., Azar, I., Xiu, J., Hall, M. J., Hendifar, A. E., Lou, E., Hwang, J. J., Gong, J., Feldman, R., Ellis, M., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-3581 · Cited by 191
The Many Facets of Therapy Resistance and Tumor Recurrence in Glioblastoma
Goenka, A., Tiek, D., Song, X., Huang, T., Hu, B., & Cheng, S.-Y. (2021) · Cells · doi:10.3390/cells10030484 · Cited by 169
Genomic instability, inflammatory signaling and response to cancer immunotherapy
Chen, M., Linstra, R., & van Vugt, M. A. T. M. (2022) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188661 · Cited by 166
Gut OncoMicrobiome Signatures (GOMS) as next-generation biomarkers for cancer immunotherapy
Thomas, A. M., Fidelle, M., Routy, B., Kroemer, G., Wargo, J. A., Segata, N., & Zitvogel, L. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00785-8 · Cited by 141
Chemotherapy resistance in epithelial ovarian cancer: Mechanisms and emerging treatments
Marchetti, C., De Felice, F., Romito, A., Iacobelli, V., Sassu, C. M., Corrado, G., Ricci, C., Scambia, G., & Fagotti, A. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.08.011 · Cited by 139
Nassar, A. H., Adib, E., Abou Alaiwi, S., El Zarif, T., Groha, S., Akl, E. W., Nuzzo, P. V., Mouhieddine, T. H., Perea-Chamblee, T., Taraszka, K., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.08.022 · Cited by 121
Chida, K., Kawazoe, A., Kawazu, M., Suzuki, T., Nakamura, Y., Nakatsura, T., Kuwata, T., Ueno, T., Kuboki, Y., Kotani, D., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0401 · Cited by 110
Bockorny, B., Macarulla, T., Semenisty, V., Borazanci, E., Feliu, J., Ponz-Sarvise, M., Abad, D. G., Oberstein, P., Alistar, A., Muñoz, A., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0929 · Cited by 92
“Even in patients with microsatellite instability-high tumors, the response rate is less than 20% (10).”
BackgroundSelf-citationThe role of DNA damage repair (DDR) system in response to immune checkpoint inhibitor (ICI) therapy
Shi, C., Qin, K., Lin, A., Jiang, A., Cheng, Q., Liu, Z., Zhang, J., & Luo, P. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02469-0 · Cited by 85
Lenis, A. T., Ravichandran, V., Brown, S., Alam, S. M., Katims, A., Truong, H., Reisz, P. A., Vasselman, S., Nweji, B., Autio, K. A., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-3403 · Cited by 80
Hollebecque, A., Chung, H. C., de Miguel, M. J., Italiano, A., Machiels, J.-P., Lin, C.-C., Dhani, N. C., Peeters, M., Moreno, V., Su, W.-C., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0261 · Cited by 65
Self-citationPancreas cancer and BRCA : A critical subset of patients with improving therapeutic outcomes
Momtaz, P., O’Connor, C. A., Chou, J. F., Capanu, M., Park, W., Bandlamudi, C., Berger, M. F., Kelsen, D. P., Suehnholz, S. P., Chakravarty, D., et al. (2021) · Cancer · doi:10.1002/cncr.33812 · Cited by 44
Targeting DNA damage repair pathways in pancreas cancer
Crowley, F., Park, W., & O’Reilly, E. M. (2021) · Cancer and Metastasis Reviews · doi:10.1007/s10555-021-09983-1 · Cited by 43
De Lellis, L., Veschi, S., Tinari, N., Mokini, Z., Carradori, S., Brocco, D., Florio, R., Grassadonia, A., & Cama, A. (2021) · Cancers · doi:10.3390/cancers13163946 · Cited by 40
“Similarly, treatments based on immune checkpoint inhibitors (ICIs) may be potentially beneficial in PC patients with defective mismatch repair (MMR), who ideally have highly immunogenic tumors, but unfortunately, only modest results were obtained in such patients [5].”
BackgroundAmodio, V., Lamba, S., Chilà, R., Cattaneo, C. M., Mussolin, B., Corti, G., Rospo, G., Berrino, E., Tripodo, C., Pisati, F., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2022.12.003 · Cited by 39
Sholl, L. M., Awad, M., Basu Roy, U., Beasley, M. B., Cartun, R. W., Hwang, D. M., Kalemkerian, G., Lopez-Rios, F., Mino-Kenudson, M., Paintal, A., et al. (2024) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2023-0536-cp · Cited by 38
Gu, M., Gao, Y., & Chang, P. (2021) · Cancers · doi:10.3390/cancers13102429 · Cited by 35
“Currently, ICB therapy with pembrolizumab is recommended as the first-line therapy for metastatic CRAC with the MSI-H/dMMR phenotype, which has been confirmed as a reliable biomarker for predicting the outcome of ICB therapy by several lines of trial data [4,90,91].”
BackgroundPrincipe, D. R., Underwood, P. W., Kumar, S., Timbers, K. E., Koch, R. M., Trevino, J. G., Munshi, H. G., & Rana, A. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.806963 · Cited by 35
Jamal, R., Messaoudene, M., de Figuieredo, M., & Routy, B. (2023) · Seminars in Immunology · doi:10.1016/j.smim.2023.101754 · Cited by 31
Pembrolizumab for advanced cervical cancer: Safety and efficacy
De Felice, F., Giudice, E., Bolomini, G., Distefano, M. G., Scambia, G., Fagotti, A., & Marchetti, C. (2021) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2021.1850279 · Cited by 30
Koeneman, B. J., Schreibelt, G., Gorris, M. A. J., Hins - de Bree, S., Westdorp, H., Ottevanger, P. B., & de Vries, I. J. M. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1368103 · Cited by 24
Management of Refractory Pediatric Sarcoma: Current Challenges and Future Prospects
Pushpam, D., Garg, V., Ganguly, S., & Biswas, B. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s193363 · Cited by 16
Barber, E. L., Chen, S., Pineda, M. J., Robertson, S. E., Hill, E. K., Teoh, D., Schilder, J., O'Shea, K. L., Kocherginsky, M., Zhang, B., et al. (2022) · Cancer Research Communications · doi:10.1158/2767-9764.crc-22-0147 · Cited by 9
Alcindor, T., Papke, D. J., Venkataraman, V., Wagner, M. J., Merriam, P., Haddox, C. L., Wagner, A. J., Solimini, N. L., Jambhekar, A., & George, S. (2026) · JCO Precision Oncology · doi:10.1200/po-26-00414
Metadata
- Authors
- Marabelle, A., Le, D. T., Ascierto, P. A., Di Giacomo, A. M., De Jesus-Acosta, A., Delord, J.-P., Geva, R., Gottfried, M., Penel, N., Hansen, A. R., Piha-Paul, S. A., Doi, T., Gao, B., Chung, H. C., Lopez-Martin, J., Bang, Y.-J., Frommer, R. S., Shah, M., Ghori, R., Joe, A. K., Pruitt, S. K., & Diaz Jr, L. A.
- Venue
- Journal of Clinical Oncology
- Published
- 2020-01-01
- Volume
- 38
- Issue
- 1
- Pages
- 1-10
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2984359187
- Cited by
- 3,048
- References
- 22
- FWCI
- 114.36
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.